About UsAbout UsServicesProductsNews & EventsContact Us
About Us



News & Events

Contact Us

A Strategic Assessment of Oncology Innovations

The objective of this report, issued September 1998, is to identify, critique, and rate emerging cancer technologies available for in-licensing. The analyses are fresh and discriminating - both the merits and the pitfalls of each technology have been stringently reviewed against a number of relevant criteria embracing both product (e.g., mode of action) and company source (e.g., management, pipeline). In the final analysis, readers will be uniquely positioned to act quickly on expanding or launching their cancer product line.

Table of Contents

Action Report
I. Executive Summary
II. Introduction
III. Report Methodology
IV. Market/Technology Dynamics
V. Breast Cancer
VI. Colorectal Cancer
VII. Hepatobiliary Cancer
VIII. Non-Hodgkins Lymphoma
IX. Non-Small Cell Lung Cancer
X. Ovarian Cancer
XI. Pancreatic Cancer
XII. Prostate Cancer
XIII.-XXII. Novel Oncology Products/Technologies Under Clinical Development
XXIII. Reimbursement
XXIV. Conclusions
XXV. Appendices

Oncology Panelists

Roland Greenberg, Ph.D.
Troy Technology Consulting, Inc.

Darlene W. Hayes
Attorney at Law
Gray Cary Ware & Freidenrich LLP

Ian Hicks
Hicks Associates

Steven M. Larson, M.D.
Chief, Nuclear Medicine Service
Department of Radiology
Memorial Sloan-Kettering Cancer Center

Isadore Pike, M.D.
Vice President, Clinical & Medical Operations
Quintiles Oncology Therapeutics

Alan Saven, M.D.
Head of Cancer Division
Scripps Cancer Center

Oncology Editorial Board

Malin Dollinger, M.D., F.A.C.P.
Medical Oncology
John Wayne Cancer Institute

John C. Reed, M.D., Ph.D.
Scientific Director
The Burnham Institute

Branimir I. Sikic, M.D.
Director, General Clinical Research Center
Professor of Medicine
Stanford University School of Medicine

H. William Strauss, M.D.
Chairman of Nuclear Medicine
Stanford University School of Medicine

© 2024 BeckerPharmaceuticals. All Rights Reserved.